P262 Experience of palivizumab administration in prevention of respiratory syncytial virus (RSV) in children from the risk group

    loading  Checking for direct PDF access through Ovid



52 children with bronchopulmonary dysplasia underwent RSV prevention care at our Clinic over the period from 2012 to 2015. Immunisation was done in the period of seasonal spread of disease to the children with high risk complications from RSV – who were borne on the 35th week of pregnancy and earlier, having bronchopulmonary dysplasia at the age of under 2 year. Every child from the group was given minimum 3 injections and maximum 4 injections with recommended by instruction interval in 30 days±10 days.

patients characteristics

Palivizumab immunisation was done to 52 children: 26 boys and 26 girls. The age at the beginning of immunisation was 1–22 months. 10 children (19,2%) except with BPD had hemodynamically relevant heart diseases. Gestational age was 22–36 weeks. In the group of children immunised against RSV, children with critically low body mass at birth was 44,2% (23 children), very low – 19,2% (10 children) and 36,6% (19 children) low. The medicine was injected every month with interval 30±5 days in the amount of 15 mg/kg.


Efficiency analysis of immunisation was conducted on the basis of data from patients who finished the course of immunisation (at least 3 injections). At the time of immunisation 11 children (21%) suffered from ARVI in mild or moderate forms, among them 3 were taken to hospital. The disease of none of the children taken to hospital with ARVI was not connected with RSV. Besides none of the children showed signs of side effects from the treatment.


These findings based on our experience of Palivizumab administration in patients with BPD demonstrate perspectives of treatments of the patients with intractable disease.

Related Topics

    loading  Loading Related Articles